Cancer outcomes research—a European challenge: measures of the cancer burden

Molecular Oncology

Mette Kalager¹  Hans‐Olov Adami¹  Paul W. Dickman²  Karen Steindorf³  Pernilla Lagergren⁴ 

[1] Clinical Effectiveness Research Group University of Oslo and Oslo University Hospital Norway;Department of Medical Epidemiology and Biostatistics Karolinska Institutet Stockholm Sweden;Division of Physical Activity, Prevention and Cancer National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ) Heidelberg Germany;Surgical Care Science Department of Molecular Medicine and Surgery Karolinska Institutet Karolinska University Hospital Stockholm Sweden;

关键词: cancer;    health‐related quality of life;    incidence;    mortality;    outcomes;    survival;   

DOI  :  10.1002/1878-0261.13012

来源: DOAJ

【 摘 要 】

In a mission that aims to improve cancer control throughout Europe, the European Academy of Cancer Sciences has defined two key indicators of progress: within one to two decades, overall cancer‐specific 10‐year survival should reach 75%, and in each country, overall cancer mortality rates should be convincingly declining. To lay the ground for assessment of progress and to promote cancer outcomes research in general, we have reviewed the most common population‐based measures of the cancer burden. We emphasize the complexities and complementary approaches to measure cancer survival and the novel opportunities for improved assessment of quality of life. We propose that: incidence and mortality rates are standardized to the European population; net survival is used as the measure of prognosis but with proper adjustments for confounding when temporal trends in overall cancer survival are assessed; and cancer‐specific quality of life is measured by a combination of existing questionnaires and utilizes emerging communication technologies. We conclude that all measures are important and that a meaningful interpretation also requires a deep understanding of the larger clinical and public health context.

【 授权许可】

Unknown